Parallax Volatility Advisers’s Travere Therapeutics TVTX Stock Holding History

Parallax Volatility Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-24,112	Closed	-$216K	–	2509
2023 Q3	$216K	Buy	+24,112	New	+$340K	﹤0.01%	1807
2020 Q3	–	Sell	-19,999	Closed	-$408K	–	3183
2020 Q2	$408K	Buy	+19,999	New	+$318K	﹤0.01%	2035
2019 Q4	–	Sell	-1,101	Closed	-$13K	–	2654
2019 Q3	$13K	Buy	+1,101	New	+$18.2K	﹤0.01%	2169
2018 Q4	–	Sell	-5,026	Closed	-$144K	–	3959
2018 Q3	$144K	Buy	+5,026	New	+$144K	﹤0.01%	1676
2018 Q1	–	Sell	-5,796	Closed	-$122K	–	4206
2017 Q4	$122K	Buy	+5,796	New	+$132K	﹤0.01%	2672

Other funds holding TVTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Parallax Volatility Advisers's TVTX Position: Q4 2023 in Review

Parallax Volatility Advisers sold out of Travere Therapeutics (TVTX) in Q4 2023, closing a stake of 24,112 shares — an estimated $216K sold.

Parallax Volatility Advisers first reported a position in TVTX in Q4 2017 and held it in 5 quarters. The position peaked at $408K in Q2 2020. 165 funds tracked by Wall St. Rank hold TVTX as of Q4 2023.

Parallax Volatility Advisers reported no remaining Travere Therapeutics position as of Q4 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 24,112 Travere Therapeutics shares in Q4 2023, an estimated $216K.
Parallax Volatility Advisers first reported a position in Travere Therapeutics in Q4 2017 and held it in 5 quarters.
Parallax Volatility Advisers's Travere Therapeutics position peaked at $408K in Q2 2020.
165 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2023.

Based on Parallax Volatility Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.